Skip to content

First Line Prevent Age Study

First Line Prevent Age Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05361343
Acronym
FLIPS
Enrollment
100
Registered
2022-05-04
Start date
2025-02-28
Completion date
2026-09-30
Last updated
2024-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Aging, Healthy Diet, Healthy Lifestyle

Brief summary

To prove the effectiveness of complex wellness programs in terms of maintaining active longevity, including motivational counseling, high-intensity training, intermittent fasting, hypoxic training, as well as practices for achieving healthy sleep and mental well-being. Clinical-instrumental, single-centre, prospective, open-label, non-randomized, sequential enrollment study with blinded endpoint analysis

Interventions

OTHER1. Nutrition; 2. Physical activity; 3. Hypoxic training; 4. Menthal heals improvement

1. Nutrition: intermittent fasting; 2. Physical activity: medium-intensity or high-intensity physical activity; 3. Hypoxic training (at least three per visit to the center); 4. correction of hygiene and sleep duration, relaxation techniques, cognitive behavioral therapy for insomnia. 5. Individual motivational counseling.

Sponsors

Prevent Age Resort Pervaya Liniya
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Men and women over 18; * No significant (affecting the functional state) active diseases: acute diseases and exacerbations of chronic diseases; * Interest in active longevity and willingness to participate in research. * Signed informed consent.

Exclusion criteria

* Age up to 18 years; * Severe or moderate comorbidities; * Rheumatological (systemic / autoimmune) diseases of any severity; * Intestinal infections (within 3 months); * SARS / pneumonia, other diseases accompanied by systemic inflammation during the last 2 months; * Chronic inflammatory bowel disease; * Major surgery within the last 3 months * Intoxication (alcohol, drugs, other toxins); * Oncological disease (except for basalioma) out of remission; * Persons with mental illness; * Diabetes; * Syndrome of obstructive sleep apnea of moderate and severe severity; * Low adherence to lifestyle interventions, including physical activity of less than 150 minutes of aerobic activity per week (at least two days per week) or 75 minutes of vigorous exercise (at least 3 days per week).

Design outcomes

Primary

MeasureTime frameDescription
improved endothelial functionFirst point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)improvement of flow-mediated vasodilatation measured by ultrasound (cuff test)
improved quality of night sleepFirst point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)improvement in nighttime sleep quality assessed by a Pittsburgh Sleep Quality Scale
Reducing the degree of anxietyFirst point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)Reduction in the degree of anxiety according to the assessment of the Spielberger test

Secondary

MeasureTime frameDescription
increased self-esteemFirst point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)increasing the level of self-esteem based on the results of the analysis of the Dembo-Rubinstein questionnaire
improved quality of night sleepFirst point: 1 week (2nd visit). Second oint after 6 - 13 months (3rd visit)improvement in nighttime sleep quality assessed by a sleep indicator scale

Countries

Russia

Contacts

Primary ContactAnna Ratnikova
ya.ashikhmin@gmail.com+7 921 303-15-33

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026